semaglutide 2.4 Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Semaglutide 2.4 mg FlexTouch at

The first pill is on its way and another is close behind Novo Nordisk's obesity pill was approved first

Because it helps reduce overeating and supports healthier habits, GLP-1 has quickly become one of the most trusted weight loss options available today

Es importante ser consciente de que estos frmacos tienen efectos secundarios como nuseas , vmitos , dolor abdominal y en algunos casos, problemas ms serios como pancreatitis o complicaciones en la vescula biliar

Conclusion: Ozempic and Wegovy can be effective medications for managing blood sugars and losing weight

Some may lose only 3% of body weight

Timing strategies can help manage these interactions